{
  "id": 12898368,
  "title": "Argenx falls as Sjögren’s setback offsets celiac drug progress",
  "url": "https://urgent.news/2026/10/08/argenx-falls-as-sjogrens-setback-offsets-celiac-drug-progress",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T15:38:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/argenx-sjogrens-vyvgart-celiac-forte-study-results/832463/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Argenx's study flop in Sjögren's overshadows a win in celiac disease",
        "url": "https://urgent.news/2026/10/08/argenxs-study-flop-in-sjogrens-overshadows-a-win-in-celiac-disease",
        "published": "2026-10-08T11:00:06.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease",
        "url": "https://urgent.news/2026/10/08/stat-argenx-sees-unusual-setback-with-failure-of-late-stage-study-of",
        "published": "2026-10-08T14:02:29.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}